Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KBP-5074 in uncontrolled hypertension with stage 3b/4 chronic kidney disease
2021-003636-88Phase 3Active
- Sponsor
- KBP Biosciences
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypertension (HTN) and chronic kidney disease (CKD) comparing KBP-5074 with Placebo (2 arms). Primary endpoint: Change in seated trough cuff systolic blood pressure from baseline to Week 12. Started May 2022; status: active.
02
Drugs
ocederenone
03
Conditions
hypertension (HTN)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2021-003636-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003636-88.